FOCUS 2024

8h30 Welcome breakfast

8h50 Congress introduction: words of the presidents

9h00 JOINT SESSION Management of histological variants
> Prostace Cancer
> Bladder cancer
> Kidney cancer
> Discussion

9h50 Place de l’intensification systémique au diagnostic : au stade métastatique / au stade localisé with the support of BAYER
> Au stade métastatique (ARANOTE)
> Au stade localisé (Neoadjuvant therapy before radical prostatectomy)
> Discussion

10h35 Coffee break and exhibition visit

11h00 BLADDER CANCER
> Bladder preservation is a SOC in muscule-invasive disease: yes / no
> BCG unresponsavice NMIBC: systemic / intravesical
> Discussion

12h00 Optimizing treatment of genitourinary cancers in 2024
> High risk non metastatic BCR or oligometastatic disease?
> NHT monotherapy : from localized to M1 disease. Where do we stand?
> Metastatic urothelial carcinoma: new treatments and sequences
> Discussion

13h00 Lunch and exhibition visit

14h00 Artificial intelligence and radiotherapy: where do we stand?

14h15 How to achieve complete response in mRCC: who and when? with the support of EISAI / MSD
> The choice of systemic treatment
> SBRT
> Favorable IMDC mCCRC: combination for everyone?
> Discussion

15h15 TESTIS AND PENILE
> RPLND in germ cell tumors: state-of-the-art
> Brachytherapy for penile cancer: state-of-the-art
> Discussion

15h45 Coffee break and exhibition visit

16h15 Session with the support of JANSSEN
Evolving landscape in mHSPC
> Data doublets/triplets
> Could biology help selecting patients?
mCRPC: how to best use PARP inhibitors
> MAGNITUDE vs PARPi alone approach / Importance to select the best treatment upfront
> PARP synergy of action in regard of preclinical models, Differentials outcomes in BRCA ½, PARPi in PCa
New data in bladder cancer
Discussion

17h15 UROTHELIAL CANCER
> Should we intensify upfront BCG treatment in high risk NMIBC
> Multimodal strategy in locally advanced upper urinary tract carcinoma
> Oligometastatic bladder cancer: truth and myths
> Discussion

18h00 SPECIAL GUEST

18h30 End of the day

9h00 Supportive care in urologic cancers with the support of IPSEN
> Role of the Adapted Physical Activity (APA) in the support of urologic cancers
> mRCC : Optimization of therapeutic care and management of tolerance: what has changed and how this impacts our practices?
> How Quality-of-life should guide our treatment decision-making

10h00 AFU READ
> SBRT for localized renal cancer
> Renaming ISUP1 : yes / no

10h30 Coffee break and exhibition visit

11h00 Adjuvant treatment in GU cancers: where do we stand in 2024? with the support of BMS
> Prostate cancer
> Urothelial cancer
> Kidney Cancer
> Discussion

12h00 PROSTATE CANCER
Loco-regional treatment of very high risk PCa (STAMPEDE M0)
> Clinical case
> Surgery (and surgical planning for high risk PCa: LND sparing, nerve preservation)
> Radiotherapy
> Discussion

13h00 Lunch and exhibition visit

14h00 LOCAL TREATMENT OPTIMIZATION
Early detection of prostate cancer
> Why we have to do it
> Why we should better delay the diagnosis
> Discussion
> Organ-sparing RC in female patients
> How to optimize SBRT in localized Pca
> Discussion

15h00 Nuclear Medicine in G-U cancer: What’s new in 2024? with the support of ADACAP
> New radiotracers in GU cancer
> Internal vectorized radiotherapy: earlier is better? M1
> Internal vectorized radiotherapy: earlier is better? M0
> Discussion

16h00 MUST READ ARTICLE

16h15 FOCUS MEETS CANADA CONCLUSION

16h30 Congress end